Skip to main
MASI

Masimo (MASI) Stock Forecast & Price Target

Masimo (MASI) Analyst Ratings

Based on 4 analyst ratings
Buy
Strong Buy 25%
Buy 25%
Hold 50%
Sell 0%
Strong Sell 0%

Bulls say

Masimo is a solid company with a focused approach on healthcare technology, and their strategic priorities including focus, innovation, and execution will continue to drive growth and profitability. They are also heavily invested in research and development, with over 80 studies planned in the next three years, which will contribute to future revenue growth. The recent agreement with Danaher for a $9.9B cash acquisition shows the value and potential of Masimo's business.

Bears say

Masimo is facing issues with predictable revenue due to fluctuations in installations and orders, as well as challenges with predicting quarterly revenue for their healthcare products. In comparison to other medical technology companies like Edwards Lifesciences Corporation and Intuitive Surgical, Inc., their financials and key metrics are relatively weaker, with slower integration of mergers and acquisitions, pricing pressure, and slower demand for capital equipment, making us have a negative outlook on the stock. However, risks to our rating and price target include unexpected positive announcements, potential improvements in competitive dynamics within the spine market, and better expense management, which could potentially increase the likelihood of achieving our $200 price target.

Masimo (MASI) has been analyzed by 4 analysts, with a consensus rating of Buy. 25% of analysts recommend a Strong Buy, 25% recommend Buy, 50% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Masimo and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Masimo (MASI) Forecast

Analysts have given Masimo (MASI) a Buy based on their latest research and market trends.

According to 4 analysts, Masimo (MASI) has a Buy consensus rating as of Jun 3, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $188, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $188, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Masimo (MASI)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.